Novartis Cuts 2,000 Jobs In Switzerland And U.S., Pricing Pressures To Blame
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis intends to improve productivity and absorb pricing pressures by closing two Swiss manufacturing facilities and transferring some research to the U.S.
You may also be interested in...
Swapping Assets Now Down To Execution For GSK And Novartis
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.
Swapping Assets Now Down To Execution For GSK And Novartis
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.
Thousands Of Jobs May Go At Novartis But Worker Headcount To Stay Flat
Novartis plans to support new product launches and other activities around the world by re-allocating up to 4,000 positions, in order to make productivity gains.